Rena Shah
YOU?
Author Swipe
View article: GammaTile® (GT) as a brachytherapy platform for rapidly growing brain metastasis
GammaTile® (GT) as a brachytherapy platform for rapidly growing brain metastasis Open
Background A subset of brain metastasis (BM) shows rapid recurrence post-initial resection or aggressive tumor growth between interval scans. Here we provide a pilot experience in the treatment of these BM with GammaTile® (GT), a collagen …
View article: GammaTile brachytherapy in the treatment of recurrent glioblastomas
GammaTile brachytherapy in the treatment of recurrent glioblastomas Open
View article: GammaTile® brachytherapy in the treatment of recurrent glioblastomas
GammaTile® brachytherapy in the treatment of recurrent glioblastomas Open
Background GammaTile® (GT) is a recent U.S. Food and Drug Administration (FDA) cleared brachytherapy platform. Here, we report clinical outcomes for recurrent glioblastoma patients after GT treatment following maximal safe resection. Metho…
View article: Rapid Interval Recurrence of Glioblastoma Following Gross Total Resection: A Possible Indication for GammaTileⓇ Brachytherapy
Rapid Interval Recurrence of Glioblastoma Following Gross Total Resection: A Possible Indication for GammaTileⓇ Brachytherapy Open
Glioblastoma recurrence between initial resection and standard-of-care adjuvant chemoradiotherapy (CRT) is a negative prognostic factor in an already highly aggressive disease. Re-resection with GammaTileⓇ(GT Medical Technologies Inc., Tem…
View article: RADT-15. FIRST EXPERIENCE WITH MAXIMAL SAFE RESECTION AND GAMMATILE BRACHYTHERAPY AS TREATMENT FOR RECURRENT GLIOBLASTOMA
RADT-15. FIRST EXPERIENCE WITH MAXIMAL SAFE RESECTION AND GAMMATILE BRACHYTHERAPY AS TREATMENT FOR RECURRENT GLIOBLASTOMA Open
INTRODUCTION Gammatile (GT) is a recently FDA-cleared brachytherapy platform with 131Cs seeds imbedded into a resorbable collagen carrier for surgically targeted radiation delivery. We report the first experience for recurrent glioblastoma…
View article: Maternal opioid dose is associated with neonatal abstinence syndrome in children born to women with sickle cell disease
Maternal opioid dose is associated with neonatal abstinence syndrome in children born to women with sickle cell disease Open
The objective of this study was to test the hypothesis that higher daily opioid dose is associated with the presence and severity of neonatal abstinence syndrome (NAS) in pregnant women with sickle cell disease (SCD). This was a retrospect…